Today, the HIV+Hepatitis Policy Institute and the North Carolina AIDS Action Network filed discrimination complaints against Blue Cross and Blue Shield of North Carolina for placing almost all HIV drugs, including generic Pre-Exposure Prophylaxis (PrEP), on the highest drug tiers, thus forcing people living with and vulnerable to HIV to pay excessive high costs to take their drugs.
In advance of World AIDS Day on December 1st, the HIV+Hepatitis Policy Institute has released a report modeling the resources needed to fund a national Pre-Exposure Prophylaxis (PrEP) program.
Preventive services covered by private insurance plans without cost- sharing, such as HIV testing, hepatitis B and C testing, and PrEP, are all critical and well-established public health preventive services that must continue. To single out PrEP, which are FDA approved drugs that effectively prevent HIV, and conclude that its coverage violates the religious freedom of certain individuals, is plain wrong, highly discriminatory, and impedes the public health of our nation. PrEP is not just for gay men, but for anyone who may be at risk of HIV.
The leadership of the United States Senate Appropriations Committee is proposing to significantly increase funding to continue to ramp up efforts to end HIV in the United States. The Senate bills include increased funding for the Ending the HIV Epidemic in the U.S. initiative by at least $240 million for domestic HIV testing, prevention, treatment, and research programs. While it is not as much as proposed in President Biden’s budget, in some instances it is more than what was proposed by the House.
The U.S. House of Representatives Labor, HHS Appropriations Subcommittee is proposing to increase funding to continue to ramp up efforts to end HIV in the United States. However, it fails to include a national program to increase access to PrEP, which are medications that prevent HIV. In addition to an increase of $225 million for domestic HIV testing, prevention, and treatment programs as part of the Ending the HIV Epidemic initiative, the FY23 Labor, HHS appropriations bill is proposing a $75 million increase to the Ryan White HIV/AIDS Program and $200 million more for NIH AIDS Research.